PYC THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.092 AUD | 0.00% |
|
+2.22% | -16.36% |
| 04-22 | Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data | MT |
| 04-22 | PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study | MT |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 206.8 | 191.3 | 411.4 | - | - |
| Enterprise Value (EV) 1 | 206.8 | 175.8 | 370.6 | 336.2 | 361 |
| P/E ratio | -14.8 x | -7.89 x | -11.6 x | -12.1 x | -55.1 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 12 x | 51.4 x | 51.4 x | 12.5 x |
| EV / Revenue | - | 11 x | 46.3 x | 42 x | 10.9 x |
| EV / EBITDA | - | -7.83 x | -12.1 x | -9.77 x | -54 x |
| EV / FCF | - | -7.05 x | -20.1 x | -17.8 x | -17.2 x |
| FCF Yield | - | -14.2% | -4.96% | -5.62% | -5.82% |
| Price to Book | - | - | 5.53 x | 3.55 x | 5.05 x |
| Nbr of stocks (in thousands) | 3,180,926 | 3,416,503 | 4,471,977 | - | - |
| Reference price 2 | 0.0650 | 0.0560 | 0.0920 | 0.0920 | 0.0920 |
| Announcement Date | 30/08/22 | 31/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 15.91 | 8 | 8 | 33 |
| EBITDA 1 | - | -22.45 | -30.59 | -34.42 | -6.682 |
| EBIT 1 | - | -23.33 | -31.31 | -35.16 | -7.433 |
| Operating Margin | - | -146.65% | -391.4% | -439.48% | -22.52% |
| Earnings before Tax (EBT) 1 | - | -23.36 | -29.7 | -24.4 | -26.6 |
| Net income 1 | -13.86 | -22.79 | -30.99 | -34.23 | -6.504 |
| Net margin | - | -143.26% | -387.34% | -427.85% | -19.71% |
| EPS 2 | -0.004400 | -0.007100 | -0.007900 | -0.007630 | -0.001670 |
| Free Cash Flow 1 | - | -24.91 | -18.4 | -18.9 | -21 |
| FCF margin | - | -156.61% | -230% | -236.25% | -63.64% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 30/08/22 | 31/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 15.6 | 40.8 | 75.3 | 50.4 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -24.9 | -18.4 | -18.9 | -21 |
| ROE (net income / shareholders' equity) | - | -82.1% | -85.4% | -58.4% | -28.3% |
| ROA (Net income/ Total Assets) | - | -61.3% | - | - | - |
| Assets 1 | - | 37.17 | - | - | - |
| Book Value Per Share 2 | - | - | 0.0200 | 0.0300 | 0.0200 |
| Cash Flow per Share 2 | - | - | -0.0100 | -0.0100 | -0.0100 |
| Capex 1 | - | 0.49 | 0.48 | 0.48 | 0.48 |
| Capex / Sales | - | 3.09% | 5.99% | 5.99% | 1.45% |
| Announcement Date | 30/08/22 | 31/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.092
AUD
Average target price
0.345
AUD
Spread / Average Target
+275.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.36% | 268M | |
| +1.51% | 42.75B | |
| +48.26% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PYC Stock
- Financials PYC Therapeutics Limited
